Prime Editing Unlocks a Universal Strategy for Restoring Lost Proteins
November 22, 2025
Background
Epidemiology
Anatomy
Pathophysiology
Etiology
Genetics
Prognostic Factors
Clinical History
Physical Examination
Age group
Associated comorbidity
Associated activity
Acuity of presentation
Differential Diagnoses
Laboratory Studies
Imaging Studies
Procedures
Histologic Findings
Staging
Treatment Paradigm
by Stage
by Modality
Chemotherapy
Radiation Therapy
Surgical Interventions
Hormone Therapy
Immunotherapy
Hyperthermia
Photodynamic Therapy
Stem Cell Transplant
Targeted Therapy
Palliative Care
Medication
10
mg
Topical
once daily for 7–14 weeks and maximum continue up to 17 weeks, after six weeks, if there is an inadequate response, then the second course of topical therapy is administered with a dose of 20 mg once daily for 4 to 8 weeks until it is tolerable
15
mg/m^2
Intravenous (IV)
once weekly for 3 – 4 weeks cycle; continue until unacceptable toxicity or disease progression.
Dose Adjustments
Adjustment in case of renal impairment:
eGFR > 30 ml/minute/1.73m2: No dose adjustment needed
eGFR 15 to 30 ml/minute/1.73m2: reduce the dose to 15 mg/m2
Avoid the use of pralatrexate for patients with end-stage renal disease, including dialysis.
Discontinue the treatment in patients with grade 3 or 4 hepatotoxicity.
Indicated for the treatment of CTCL, who have progressive, persistent, or recurrent disease on or followed by two systemic therapies :
400
mg
Orally
once a day
the dose is reduced to 300 mg orally per day if the patient is intolerant to therapy
the dose was further reduced to 300 mg once daily for five consecutive days each week if needed
continue the treatment until progressive disease or unacceptable toxicity occurs
Dose Adjustments
Renal Dose Adjustments:
Caution recommended.
Liver Dose Adjustments:
starting dose reduced to 300 mg orally once daily for mild to moderate hepatic impairment bilirubin 1-3 x ULN or AST > ULN
Data not available for severe hepatic impairment bilirubin > 3 x ULN
Indicated for the treatment of CTCL and peripheral T-cell lymphoma (PTCL) in patients who have received at least one before systemic therapy :
14
mg/m^2
Intravenous (IV)
over 4 hr
on days 1, 8, and 15 for a 28-day cycle course
Continue to repeat the cycle every 28 days till the patient's disease progression or intolerable toxicity occurs
Apply every 12 hours to the cutaneous lesion
orally /strong>
Take orally with food or milk 2 hour before exposure to UVA
0.6 mg/kg initially
administer initial dose combined with 10 mg after 24 hr, if serum concentration <50 ng/mL
Parenteral
200 mcg (10 mL) inject into the photoactivation bag for UVAR photopheresis system
300 mg/m² orally daily with the food; titrate according to toxicity or response; if there is no improvement after 8 weeks of treatment, increase the dose to 400 mg/m2/day
Topical: Apply on to the lesions every alternate day for one week, following may increase every week to every 4 times a day.
Monitor: thyroid function, cholesterol levels, and WBCs.
Sezary Syndrome or Refractory Mycosis Fungoides (Off-label)
75-150 mg orally daily in combination with the PUVA; should not exceed more than 300 mg/day
Dose Adjustments
Hepatic Impairment
use caution; Not known
Renal Impairment
use caution; Not known
Put a layer of thin film of gel on upper surface of the skin to impacted areas one time a day
Dosage Modifications
Skin toxicities
After 7 days at every 3 days, can raise the frequency to alternate days for a minimum of 7 days, and then to once per day if it is bearable
Administration
Apply once or inside half-hour after elimination from the fridge and put back gel to the fridge at once after every use
Apply to absolutely dry skin at least four hours earlier
Allow targeted regions to dry for 5 to 10 minutes after application earlier than protecting with clothing
Emollients can be implemented to the targeted regions 2 hour earlier
Avoid flame, smoking and fire till the gel has dried
Avoid dressings on regions of skin where gel is used
Indicated for Mycosis fungoides-type cutaneous T-cell lymphoma:
On affected skin, apply a thin layer once a day
Indicated for Mycosis fungoides-type cutaneous T-cell lymphoma:
On affected skin, apply a thin layer once a day
Future Trends
References

Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.

On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.

When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
